Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC

Summary

Through the neoadjuvant treatment with a combination of Pucotenlimab and Vorolanib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)

Timeline

Start

2025-07-10

Primary completion

2026-12-31

Completion

2026-12-31

Drugs

Indications